Mantis Biotech is doubling down on digital twins—virtual replicas of human anatomy and physiology—to generate synthetic datasets that could sidestep one of healthcare AI’s biggest bottlenecks: access to high-quality, diverse patient data.

Announced March 30, 2026, the company’s push comes as privacy regulations and fragmented data-sharing practices continue to choke the flow of real-world medical data. For AI developers, that means limited training material, biased models, and slow progress. Mantis is betting its synthetic data platform can break this logjam.

Digital Twins: More Than a Buzzword

Digital twins aren’t just 3D avatars—they’re high-fidelity, dynamic models engineered to mimic the complexities of human biology. Mantis Biotech’s approach lets researchers simulate everything from cardiovascular function to drug metabolism, generating synthetic patient records at scale.

What’s different here? The company claims its digital twins can be tuned to represent diverse demographics, disease states, and rare conditions—attributes sorely lacking in most real-world datasets. That’s a big deal for AI, where lack of diversity translates directly into algorithmic blind spots.

Why Synthetic Data Matters Now

Healthcare AI is projected to reach a $188 billion market by 2030, according to Statista and MarketsandMarkets. But progress depends on data—lots of it, and from all corners of the population. Privacy laws like HIPAA and GDPR, plus institutional reluctance to share, have left researchers scrambling for alternatives.

Synthetic data, generated from digital twins, offers a workaround. It’s not linked to real patients, so it sidesteps privacy concerns and regulatory headaches. And with the synthetic data market in healthcare projected to grow at over 30% CAGR through 2030, per industry estimates, this is no fringe experiment—it’s a fast-moving trend.

Applications: Beyond the Dataset

Mantis Biotech’s synthetic datasets are designed for more than just training AI models. The company is targeting three main use cases:

• Diagnostics: Training algorithms to spot diseases across diverse populations and rare presentations
• Treatment Planning: Simulating patient responses to interventions, supporting personalized medicine
• Drug Discovery: Validating new compounds and predicting side effects without waiting for real-world trials

By generating data that’s both rich and customizable, Mantis aims to improve the generalizability—and ultimately the safety—of AI in clinical settings. That’s a critical step, given repeated concerns about algorithmic bias and the reproducibility crisis in medical AI.

Regulatory and Ethical Headwinds

One of the thorniest issues in healthcare AI is navigating the regulatory maze around patient data. Synthetic data, if validated, could offer a way forward. Mantis Biotech’s pitch is that digital twins can help companies and researchers get past ethical and legal roadblocks without compromising on model performance.

Still, synthetic data isn’t a cure-all. The quality of the digital twin determines the value of the data it generates. If the models are off, so are the insights. That’s why transparency in how these twins are built—and how closely they mirror real-world biology—will be under the microscope as adoption grows.

What to Watch Next

Mantis Biotech, founded in 2023, is part of a broader deep-tech wave betting on simulation and synthetic data to fuel AI’s next leap in healthcare. As the sector races toward $188 billion in value, the ability to generate, validate, and deploy synthetic datasets could become a key competitive differentiator—not just for startups, but for the entire ecosystem.

The next big questions: Can digital twins truly capture the messiness of real patients? Will regulators accept synthetic data as a proxy for the real thing? And how quickly will incumbents pivot from hoarding data to embracing simulation-driven innovation? Watch this space—because the future of healthcare AI may be built on data that never existed.